Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGF- β1

Lung cancer is a heterogeneous disease in which patient-specific treatments are desirable and the development of targeted therapies has been effective. Though mutations in KRAS are frequent in lung adenocarcinoma, there are currently no targeted agents against KRAS. Using a mouse lung adenocarcinoma...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer Res
Egile Nagusiak: Sippel, Trisha R, Johnson, Amber M, Li, Howard Y, Hanson, Dwight, Nguyen, Teresa T, Bullock, Bonnie L, Poczobutt, Joanna M, Kwak, Jeff W, Kleczko, Emily K, Weiser-Evans, Mary C, Nemenoff, Raphael A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7439607/
https://ncbi.nlm.nih.gov/pubmed/31088909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-0236
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak